Launch of European Benchmark Clinical Studies

A group of public and private organisations is joining forces for a benchmark of drug studies in the clinical phases. The goal is to gain insight into the Dutch landscape of clinical studies and make a comparison with other countries in Europe.

The principals, Health~Holland, FAST, Invest-in-Holland, CCMO, DCRF, ACRON and the VIG* want to make the Netherlands more attractive for organising, reviewing and conducting drug research. 'We are pleased to be able to combine our expertise and strengths and we look forward to the results,' said the joint parties.

Clinical research

Clinical studies are needed to develop new treatments. This is important primarily for patients. For some people, current treatments do not work adequately, the treatments may cause unwanted side effects, or they may not be user-friendly. For others, there may be no effective treatment for their medical condition. Clinical studies may then be a solution toward better treatment. In addition, clinical studies provide a constant flow of new, scientific knowledge and investment that contributes to the economy of the Netherlands.

Benchmark                           

The benchmark will provide an overview of the studies conducted in the Netherlands and how they relate to other countries in Europe. This will include looking at the number of studies in different phases, the number of participants, common indications and turnaround times of clinical studies. 'With this information, we can look specifically at which areas the Netherlands excels internationally, and what we can learn from other countries,' adds a spokesperson.

Leader

The high population density combined with a well-functioning infrastructure of (academic) hospitals mean that the Netherlands has a unique position in the field of clinical research. According to the joint parties, the Netherlands has everything it needs to become a European leader in clinical research: 'The insights provided by the research and benchmark can make an important contribution to this.'

The results of the study are expected and presented in the course of the year.

*Names of the organisations abbreviated; Centre for Future Affordable Sustainable Therapy Development (FAST), Central Committee on Research Involving Human Subjects (CCMO), Dutch Clinical Research Foundation (DCRF), Association of Contract Research Organisations Netherlands (ACRON), Association Innovative Medicines(VIG)

Source: ACRON